Degludec's Japanese launch delayed as Novo holds out on pricing
This article was originally published in Scrip
Executive Summary
Japan may have been the first country worldwide to grant a regulatory approval to Novo Nordisk's insulin degludec product Tresiba, but the once-daily basal insulin analog will not now be launched in the country until next year, possibly after it reaches its first European markets.